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Abstract 
Objective: The purpose of the research is to test the measurement of the total urinary volume, induced by the diu-
retic osmotic action of mannitol, in a group of symptomatic MD patients and in healthy controls.
Results: An altered excretory urinary volume after mannitol challenge was observed in symptomatic MD 
(874.3 ± 302.1) compared to healthy volunteers (361.7 ± 181.6) (p = 0.0001). This easy and self-administered method 
might be proposed to replace the analysis of the urinary sugars’ concentration in symptomatic MD patients.
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Introduction
In 1923, inhalant and food allergies have been related 
to Ménières’ disease (MD) [1]; from then until now, this 
relation has been reported in the literature [2–7]. Since 
2013, increased intestinal permeability has been shown 
to be an intrinsic trait in a subset of food allergic subjects 
[8, 9].
The urinary excretion of two orally administered non-
metabolizable sugars, lactulose and mannitol, also known 
as the “double sugar test” is a well-known, validated, 
non-invasive method to evaluate the intestinal perme-
ability, because their urinary concentration is an indirect 
index of their intestinal absorption [10]. The results are 
expressed as the ratio of lactulose and mannitol recov-
ered in the urine; it is a reliable marker, independent 
from the etiology of altered intestinal permeability and 
from the methods of collection [11]. It has been also con-
sidered for screening purposes in different clinical con-
ditions, especially in children, in order to avoid more 
invasive tests, or in the assessment of the responses to 
new treatments [12].
By means of this method, we recently identified an 
altered intestinal permeability in symptomatic Ménière 
disease (MD) patients [13]. In particular, the most con-
sistent rise was observed for mannitol (vs. lactulose) in 
symptomatic MD patients; therefore, we hypothesized 
the possible use of the mannitol challenge as a stand-
alone test to detect a condition of altered intestinal per-
meability. We also noticed that an increase of urinary 
mannitol was also associated with an increase in the 
total volume of the urines, but this finding was initially 
considered less relevant than the ratio between the con-
centration of the two sugars. Mannitol infusion induces 
polyuria by an osmotic mechanism: the total diuresis 
exceeds 3000  ml/24  h and the osmolarity reaches 300 
mOsmol/L [14].
The aim of this study was to check if the measure-
ment of the total urinary volume, induced by the diu-
retic osmotic action of mannitol, can replace the analysis 
of the urinary sugars’ concentration. For this reason, we 
compared the total urine volume collected in the 4  h 
following the water load containing a pre-determined 
mannitol amount in symptomatic MD patients and in a 
healthy control group.
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Main text
Methods
Patients
The study included 19 adult subjects extracted from a 
pool of 186 unilateral definite MD patients recruited at 
the outpatient clinic of the Vestibular Disorders Unit 
in a tertiary referral university Hospital during the last 
3 years. They were 12 females and 7 males (mean age: 
57.0 ± 10.8 years). They fulfilled all criteria for definite 
MD according to the AAO-HNS guidelines [15] and 
were negative for retrocochlear lesions at magnetic res-
onance imaging.
MD patients were included if:
1. altered intestinal permeability was previously con-
firmed by the validated “double sugar test” and faecal 
calprotectin > 50 μg/g;
2. they were “symptomatic” from a vestibular point of 
view, i.e. they suffered at least two major episodes of 
vertigo per month with sensorineural hearing loss 
and aural fullness during the 3  months prior to the 
admission, and
3. had a functional level (FL) ≥ 4, according to the con-
sensus paper guidelines [15].
Exclusion criteria were:
1. a positive history for gastrointestinal disease, hyper-
tension, celiac or bowel disease;
2. abnormal thyroid hormones;
3. history of malignant tumours or autoimmune dis-
eases;
4. specific diets (including low-salt [Na/K] intake).
Those patients who had previously received systemic 
steroids or intratympanic injections (either gentamicin 
or steroids) were also excluded from the study, as well 
as those being treated with diuretics, protonic pump 
inhibitors and/or antihistamines.
Controls
Fourteen healthy volunteers (10 females, 4 males, mean 
age: 42.0 ± 17.0  years) served as a “control group”, in 
order to check the reference values. All healthy subjects 
were normally hearing, reported a negative familiar and 
personal history of vertigo or dizziness, and never suf-
fered from otological diseases. In the inclusion criteria, 
they should have never suffered from gastrointestinal 
diseases, they should have a negative familiar history 
for intestinal bowel disease or celiac disease. They had 
a negative “double sugar test” and faecal calprotectin 
was < 50 μg/g.
Test
The standardized procedure described as the “double 
sugar test” [13] was modified by testing only manni-
tol. When awakening in the morning, each patient was 
instructed to collect and evaluate the volume of a pre-test 
urine sample. Then, they were asked to drink a solution 
containing 1 g mannitol dissolved in 200 ml water. Urines 
were collected during the next 4 h and the total volume 
was measured. Patients were instructed to avoid eating 
(not even a chewing-gum), drinking or smoking during 
the test, but were allowed to drink a fixed dose of water 
(200 ml), only half an hour after the test start.
Statistical analysis
Statistical analysis was performed using the SPSS sta-
tistical package version 24.00 (SPSS Inc., Chicago, Illi-
nois). The significance of difference between the two 
groups compared with each other was evaluated by 
U-Mann–Whitney test for independent samples. Results 
are expressed as means and standard deviations (SD). A 
p < 0.05 was considered statistically significant.
Results
MD patients were homogeneous as per onset time of MD 
(> 5 years), degree of hearing loss (stage 2) and absence of 
comorbidities. MD and control group resulted compara-
ble for age and sex.
The volumes of urine collected upon awakening (base-
line) were similar in the two groups: 323.7 ± 138.4 (MD) 
vs 393.2 ± 299.5 (controls), (p = n.s).
A significant increase of volume of the urine collected 
for 4 h following the water load containing mannitol was 
found in symptomatic MD, compared to healthy volun-
teers: 874.3 ± 302.1 vs 361.7 ± 181.6 (p = 0.0001), respec-
tively (Fig. 1).
Discussion
Mannitol is an osmotic diuretic used to prevent acute 
tubular necrosis [16]. It is occasionally useful in enhanc-
ing the diuresis in patients with severe resistant oedema 
[17]. It has been administered also to MD patients with 
the purpose of possibly reducing the endolymphatic 
hydrops [18, 19].
In healthy subjects, about 14% of mannitol adminis-
tered orally is absorbed through the hydrophilic pores 
of the enterocytes. In the active phases of MD, we pre-
viously observed an increase of mannitol and lactulose 
intake as expression of the altered intestinal permeabil-
ity [13]. We then speculated that the mucosal inflam-
mation related with food or aeroallergens intolerance, 
unleashed by immunological cross-reaction in sympto-
matic MD patients, could have impaired the intestinal 
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barrier function and induced a greater sugar absorp-
tion. Mannitol was the most sensitive between the two 
sugar challenges in this respect.
Mannitol behaves like an osmotic diuretic, i.e. it 
increases the excretion of water by the kidneys and the 
global volume of urine. Its mechanism of action does 
not involve a specific site in the kidney: it accumulates 
in the intercellular space, drawing water out of the cells 
due to increased local osmolarity. The fluids accumu-
lated in the interstitial spaces are then rapidly elimi-
nated as urine. An increased absorption of mannitol 
in case of altered intestinal permeability determines a 
decrease in sodium and an increase in serum osmolar-
ity a consequently an increase in diuresis [12].
The peculiar physical and chemical properties of 
mannitol make it an ideal tool to test the osmotic fluid 
retention in different condition of intestinal absorption, 
given the reliability of the “single paracellular permea-
tion model”, regardless of the cause of the altered intes-
tinal permeability [20].
Our new preliminary observations in a selected sam-
ple of MD patients in an active stage of the disease (1) 
confirm the hypothesis of an altered intestinal perme-
ability on the basis of a single sugar test (instead of the 
double-sugar); (2) may suggest the assessment of intes-
tinal permeability by a mannitol challenge without dos-
age of its urinary concentration but simply measuring 
the diuresis of the 4  h following the water + mannitol 
load.
This proposed method would significantly reduce costs, 
compared to the validated non-invasive “double-sugar 
test”, providing an easy and self-administered way to 
identify altered intestinal permeability.
As far as we know, this is the first report of increased 
excretory urinary volume after mannitol challenge in a 
group of symptomatic MD patients.
The strength of this work is the very selected and 
homogeneous sample population, that includes only 
symptomatic, untreated MD patients, with no drug 
interferences.
Limitations
The main drawback is the small size of the sample group 
and, in order to validate this method, further studies 
should be performed on larger populations. The method 
should be tested also in other diseases with altered intes-
tinal permeability conditions, in order to define if this 
finding is peculiar of MD. Other serologic and faecal 
parameters of altered intestinal permeability might be 
related to this new parameter.
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